# AstraZeneca: Observational study in Neurofibromatosis Type 1 (NF1) (800 participants)

**Score:** 75/100

| Field | Value |
|---|---|
| Sponsor | AstraZeneca |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Observational Study of the Real-world Effectiveness and Safety of Selumetinib Treating Adult Patients With Neurofibromatosis Type 1 (NF1) Who Have Symptomatic, Inoperable Plexiform Neurofibroma (PN) |
| NCT ID | NCT07888517 |
| Phase | Observational |
| Status | recruiting |
| Conditions | Neurofibromatosis Type 1 (NF1) |
| Target enrollment | 800 |
| Site countries | China |
| Posted | 2026-10-22 |
| Planned start | 2026-09-28 |
| Event | Newly registered study |
| Event date | 2026-10-22 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- 800 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07888517). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.